Close Menu

LAMP

The Branford, Connecticut-based startup plans to seek US Food and Drug Administration clearance for and launch its instrument and first assays in 2021.

The Dublin, Ireland-based company plans to launch its new instrument by the end of 2021 and will pursue CLIA waiver in the US.

The company received support from a Johns Hopkins University center focused on point-of-care device development for sexually transmitted infections.

The test for P. vivax-associated malaria was developed with support from FIND and will be distributed by Human Diagnostics Worldwide.

The researchers said that affordable tests that can differentiate malaria from similar diseases is vital for administering the most targeted treatment for patients.

The researchers built a combination nucleic acid-antibody test for the disease using an approach they said could be generally useful for rapid test development.

Japanese researchers developing the method highlighted its ability to accurately and rapidly diagnose different strains of malaria in resource-limited endemic regions. 

A new assay uses digital loop-mediated isothermal amplification (dLAMP) to perform phenotypic antibacterial susceptibility testing in 30 minutes.

The test leverages loop mediated isothermal amplification technology and enables the rapid detection of Neisseria meningitidis directly from cerebrospinal fluid samples.

Researches are advancing it mainly for use in mosquito surveillance efforts, but also collected data supporting clinical testing of human samples.

Pages

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.